Growth hormone

Sermorelin

GHRH(1-29), formerly Geref

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone and was once FDA-approved as Geref for children with growth hormone deficiency. The brand was discontinued for business reasons, and today it is mainly prepared by compounding pharmacies.

Key facts

  • Commonly discussed for: supporting natural growth hormone levels in adults.
  • Evidence (C): Its approval rested on pediatric growth studies, such as a 110-child Geref study where height velocity roughly doubled over 6 months. Evidence for the adult wellness uses it is discussed for today is small and largely uncontrolled.
  • FDA status: Compoundable. FDA withdrew the Geref approvals in June 2009 at the maker's request and determined in March 2013 that they were not withdrawn for safety or effectiveness reasons, which compounders cite as the basis for 503A compounding.
  • Legitimate access: Rx compounded (503A).
  • Last reviewed: October 1, 2026.

Read the deep dives

Common questions

What is the FDA 503A status of sermorelin?

As of October 2026, sermorelin is not on the FDA 503A bulks list and is not in any of the three 503A nomination categories (FDA list updated May 14, 2026). Compounding pharmacies rely on its history as the active ingredient of Geref, a formerly FDA-approved drug whose withdrawal FDA determined in 2013 was not for safety or effectiveness reasons.

Can a 503A pharmacy compound sermorelin?

Yes, with a prescription from a licensed provider for a specific patient. 503A pharmacies work from individual prescriptions, and sermorelin is widely compounded on that basis because of its prior approval as Geref.

What about 503B outsourcing facilities?

FDA lists sermorelin acetate in 503B Category 1 (under evaluation) and marks it as a component of an FDA-approved drug (list updated March 21, 2025). Under its interim policy, FDA does not intend to take action against outsourcing facilities using Category 1 substances when the policy conditions are met.

Sources